Connect with us

Hi, what are you looking for?


Lilly’s Alzheimer’s drug setback is ‘not a thesis-breaker’

buy lilly stock despite alzheimer's drug setback

Eli Lilly & Co (NYSE: LLY) ended slightly down on Friday after the U.S. FDA rejected its request of accelerated approval for Donanemab – its Alzheimer’s drug.

Why did the FDA reject its application?

According to the Food and Drug Administration, the pharmaceutical behemoth lacked sufficient data to justify fast-track approval. In particular, the regulator wants Lilly to treat at least 100 people with Donanemab for twelve months or more.

Phase II data that the Indiana-based Eli Lilly submitted fell six short of that threshold. In the press release, Anne White – the Executive Vice President of the company said:

We look forward to our upcoming confirmatory Phase 3 results and subsequent FDA submission. We’re committed to working with the FDA to ensure the fastest possible path to bring this potential medicine to patients in need.

Lilly stock is currently up more than 15% versus late September.

Should you still buy the Lilly stock?

Despite the setback, Bank of America analyst Geoff Meacham remains bullish on the pharma stock for its Mounjaro drug.

Mounjaro is Lilly’s type-2 diabetes drug that is likely to win approval to also treat obesity in the back half of 2023 (read more).

It’s definitely not a thesis-breaker. People use weakness to buy the stock, and it’s really because the narrative on obesity and on the Mounjaro launch is just so strong.

Eli Lilly & Co did not lower its full-year financial guidance after the FDA’s rejection either. Meacham currently has a price objective of $390 a share on the Lilly stock, which represents about a 13% upside from here.

The post Lilly’s Alzheimer’s drug setback is ‘not a thesis-breaker’ appeared first on Invezz.

You May Also Like


Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...


Artificial Intelligence has been the buzz word in financial markets ever since Microsoft announced its multibillion-dollar investment in ChatGPT (read more). According to Futurum...


“I will make no apologies that we are investing to make America strong. Investing in American innovation, in industries that will define the future,...


Mimiq, Inc is announcing today the launch of their new product, Mimiq Track, at CES as part of their latest product line to operate...

Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023